Avalo Therapeutics (NASDAQ:AVTX) CFO Christopher Ryan Sullivan Sells 10,185 Shares

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Sullivan sold 10,185 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $17.62, for a total transaction of $179,459.70. Following the sale, the chief financial officer directly owned 39,900 shares in the company, valued at $703,038. The trade was a 20.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Avalo Therapeutics Price Performance

Avalo Therapeutics stock opened at $16.12 on Friday. Avalo Therapeutics, Inc. has a one year low of $9.54 and a one year high of $24.27. The business has a fifty day moving average price of $19.07 and a 200-day moving average price of $17.05. The firm has a market capitalization of $864.52 million, a P/E ratio of -3.69 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.25). Sell-side analysts expect that Avalo Therapeutics, Inc. will post -2.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Avalo Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System purchased a new stake in shares of Avalo Therapeutics in the 2nd quarter valued at about $196,000. Dimensional Fund Advisors LP bought a new position in shares of Avalo Therapeutics in the third quarter worth approximately $143,000. Boothbay Fund Management LLC purchased a new stake in Avalo Therapeutics in the second quarter valued at approximately $56,000. AlphaCentric Advisors LLC bought a new stake in Avalo Therapeutics during the first quarter valued at approximately $174,000. Finally, Jump Financial LLC bought a new stake in Avalo Therapeutics during the fourth quarter valued at approximately $238,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AVTX has been the topic of several analyst reports. Wall Street Zen cut Avalo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. BTIG Research restated a “buy” rating and issued a $58.00 price objective on shares of Avalo Therapeutics in a research report on Tuesday, June 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Avalo Therapeutics in a research note on Friday, July 24th. HC Wainwright decreased their target price on shares of Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Finally, Guggenheim set a $48.00 target price on shares of Avalo Therapeutics and gave the stock a “buy” rating in a report on Friday, August 7th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Avalo Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.10.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.